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ESTATE-OF-THE-ART PAPER19333-Dimensional EchocardiographyRoberto M. Lang, Wendy Tsang, Lynn Weinert, Victor Mor-Avi, Sonal Chandra
Significant advances in 3-dimensional echocardiography (3DE) technology have ushered its
use into mainstream clinical practice. In this review, Lang and colleagues discuss the role of
3DE in evaluating valvular anatomy, volumetric quantification, pre-surgical planning,
intraprocedural guidance, and post-procedural assessment of valvular heart disease. This
technique allows more accurate quantification of valvular parameters, including orifice area,
segmental analysis of prolapse or billowing of the mitral valve, malformations of the aortic
annulus, and the extent of tricuspid annular dilation.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1945On-Treatment Platelet Reactivity Predicts Subsequent RisksSomjot S. Brar, Jurrien ten Berg, Rossella Marcucci, Matthew J. Price, Marco Valgimigli, Hyo-Soo Kim,
Giuseppe Patti, Nicoline J. Breet, Germano DiSciascio, Thomas Cuisset, George Dangas
Brar and colleagues performed a systematic meta-analysis to determine the prognostic
significance of platelet reactivity for patients taking clopidogrel. Six studies with 3,059 patients
were included. In each study, clopidogrel responsiveness was assessed using the same
VerifyNow assay (Accumetrics, San Diego, California) after percutaneous coronary
intervention (PCI) but with varying times after clopidogrel loading dose. A P2Y12 reaction
nit value 230 was associated with a higher rate of the composite primary endpoint as well
s the individual endpoints of death, myocardial infarction (MI), and stent thrombosis (ST).
his study solidifies the evidence that on-treatment platelet reactivity predicts the subsequent
isk of thrombotic outcomes after PCI.
ditorial Comment: Stephen D. Wiviott, Willibald Hochholzer, p. 1955(continued on page A-19)
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1958Eplerenone’s Benefits for Ischemic Cardiomyopathy
Are Independent of Potassium-Sparing or Diuretic EffectsPatrick Rossignol, Joël Ménard, Renaud Fay, Finn Gustafsson, Bertram Pitt, Faiez Zannad
The EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and
Survival Study) demonstrated that the mineralocorticoid receptor blocker eplerenone improved
survival in patients with acute myocardial infarction and heart failure, but the mechanism of
this benefit is not clear. Rossignol and colleagues studied this issue by testing for both diuretic
effects, estimated by changes in body weight, and potassium-sparing effects. In the eplerenone
group, body weight and plasma volume decreased and serum potassium increased at 1 month
compared with placebo-treated subjects. Both the diuretic effect and the potassium-sparing
effect were independently associated with better outcomes, but there was no statistically
significant interaction between the beneficial effects of eplerenone and either the potassium-
sparing or diuretic effects.Editorial Comment: Michele Emdin, Luigi Emilio Pastormerlo, Claudio Passino, p. 1967HEART FAILURE1970Sodium Intake Linked to Sleep Apnea in Patients With HFTakatoshi Kasai, JoAnne Arcand, Johane P. Allard, Susanna Mak, Eduardo R. Azevedo, Gary E. Newton,
T. Douglas Bradley
Kasai and colleagues have noted that sleep apnea is more common in patients with heart
failure (HF) and seems to be related to the extent of edema. The hypothesis is that this
extracellular fluid volume shifts rostrally when subjects are recumbent. For this study, the
amount of sodium intake was estimated in 54 subjects with HF who had overnight
polysomnography. The subjects with sleep apnea had higher sodium intake than those
without sleep apnea. There was also a significant correlation between the apnea-hypopnea
index and sodium intake. These findings suggest that in patients with HF, sodium intake
plays a role in the pathogenesis of sleep apnea.(continued on page A-24)
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tHEART RHYTHM DISORDERS1975Rate Control Superior to Each Antiarrhythmic Drug Used in the AFFIRM TrialSanjeev Saksena, April Slee, Albert L. Waldo, Nick Freemantle, Mathew Reynolds, Yves Rosenberg,
Snehal Rathod, Shannon Grant, Elizabeth Thomas, D. George Wyse
The AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial
showed a trend toward higher mortality and higher rates of cardiovascular outcomes in
patients assigned to a rhythm control strategy compared with those assigned to rate control.
Saksena and colleagues sought to determine whether there were significant differences
between the various antiarrhythmic drugs (AADs) that were used. The composite endpoint of
mortality or cardiovascular hospitalization was higher for all of the AADs: amiodarone
(hazard ratio [HR]: 1.18), sotalol (HR: 1.32), and Class 1C agents (HR: 1.22). These results
show minor differences in the outcomes of rate versus rhythm control based on the AAD
used, but also confirm that no AAD is superior to rate control.Editorial Comment: Steven M. Markowitz, p. 1986CARDIAC IMAGING1989Coronary CT Angiogram Can Be Used to Derive Fractional Flow ReserveBon-Kwon Koo, Andrejs Erglis, Joon-Hyung Doh, David V. Daniels, Sanda Jegere, Hyo-Soo Kim,
Allison Dunning, Tony DeFrance, Alexandra Lansky, Jonathan Leipsic, James K. Min
Fractional flow reserve (FFR) is the gold standard for identifying coronary lesions that cause
ischemia in patients undergoing invasive coronary angiography (ICA). Koo and colleagues
used computational fluid dynamics (CFD) applied to coronary computed tomographic (CT)
angiograms to noninvasively calculate fractional flow reserve (FFRCT). The measurements
ere then compared with the FFR determined during traditional angiography. On a per-
essel basis, the sensitivity and specificity of FFRCT 0.80 for predicting an FFR 0.80 were
8% and 82%, respectively. FFRCT and FFR were well correlated, with only a slight
nderestimation by FFRCT. This study shows that FFR can be determined noninvasively
hrough FFRCT with high accuracy using advanced computational fluid dynamics with data
derived from standard coronary CT scans.
Editorial Comment: Stephan Achenbach, p. 1998(continued on page A-26)
NOVEMBER 1, 2011 (continued) A-26CARDIOVASCULAR RISK2001HPV Infection May Increase Cardiovascular RiskHsu-Ko Kuo, Ken Fujise
Human papillomavirus (HPV) strains associated with cervical cancer secrete a protein that
inactivates the tumor suppressor protein p53. Inactivation of p53 has been linked to
accelerated atherosclerosis. Kuo and Fujise used data from NHANES (National Health and
Nutrition Examination Survey), where vaginal swab specimens were sent for HPV
deoxyribonucleic acid (DNA) analysis. A total of 60 female patients reported a history of
either myocardial infarction or stroke. Subjects who had the presence of cancer-associated
HPV DNA were 2.9 times more likely to have a history of cardiovascular disease after
controlling for demographics, health/sex behaviors, medical comorbidities, cardiovascular risk
factors, and management. These results further suggest a causal link between HPV infection
and cardiovascular risk.Editorial Comment: Joseph B. Muhlestein, p. 2007NEWS FROM THE NHLBI NEWS FROM THE NHLBI2010Population-Based Cohort Studies: Still Relevant?Paul Sorlie, Gina S. Wei
This commentary by Sorlie and Wei addresses the question of whether observational
epidemiology studies using a population-based cohort design continue to make an impact on
the prevention and treatment of cardiovascular disease. These types of studies, which include
the Framingham studies, have helped us to understand traditional risk factors, but are less
relevant than randomized controlled trials for guiding care. However, the authors conclude
that these studies are still useful for several topics of interest, including determining exposure
to potentially harmful substances and quickly assessing the relevance of emerging risk markers
using samples obtained from baseline examinations, whether from deoxyribonucleic acid
samples or advanced imaging studies.
